Analysts Are Bullish on These Healthcare Stocks: PRXL, ALNY

By Austin Angelo

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Parexel (NASDAQ: PRXL) and Alnylam Pharma (NASDAQ: ALNY) with bullish sentiments.

Parexel (NASDAQ: PRXL)

In a report released yesterday, Erin Wilson from Credit Suisse reiterated a Buy rating on Parexel (NASDAQ: PRXL), with a price target of $68. The company’s shares opened today at $57.05.

According to TipRanks.com, Wilson is a 4-star analyst with an average return of 5.0% and a 50.0% success rate. Wilson covers the Healthcare sector, focusing on stocks such as Dentsply International Inc., Quest Diagnostics Inc., and Phibro Animal Health.

Parexel has an analyst consensus of Moderate Buy, with a price target consensus of $67.60.

Alnylam Pharma (NASDAQ: ALNY)

Credit Suisse analyst Alethia Young reiterated a Buy rating on Alnylam Pharma (NASDAQ: ALNY) yesterday and set a price target of $50. The company’s shares opened today at $47.54.

According to TipRanks.com, Young is a 1-star analyst with an average return of -3.2% and a 39.4% success rate. Young covers the Healthcare sector, focusing on stocks such as Achillion Pharmaceuticals, Ionis Pharmaceuticals Inc, and Alexion Pharmaceuticals.

Currently, the analyst consensus on Alnylam Pharma is Moderate Buy and the average price target is $64, representing a 34.6% upside.

In a report issued on November 3, JMP Securities also reiterated a Buy rating on the stock.